| Category | Name | IntersectionWithQuery | PValue | GenesInTerm | GenesInQuery | GenesInTermInQuery | ID |
|---|---|---|---|---|---|---|---|
| GeneOntologyMolecularFunction | dynein light chain binding | 3.99e-04 | 12 | 50 | 2 | GO:0045503 | |
| GeneOntologyMolecularFunction | hydrolase activity, acting on glycosyl bonds | 4.62e-04 | 144 | 50 | 4 | GO:0016798 | |
| GeneOntologyMolecularFunction | aldose reductase (NADPH) activity | 5.49e-04 | 14 | 50 | 2 | GO:0004032 | |
| GeneOntologyMolecularFunction | alcohol dehydrogenase (NADP+) activity | 2.07e-03 | 27 | 50 | 2 | GO:0008106 | |
| GeneOntologyMolecularFunction | hydrolase activity, hydrolyzing O-glycosyl compounds | 2.19e-03 | 103 | 50 | 3 | GO:0004553 | |
| GeneOntologyMolecularFunction | phospholipase C activity | 2.39e-03 | 29 | 50 | 2 | GO:0004629 | |
| Domain | ALDOKETO_REDUCTASE_1 | 3.24e-04 | 10 | 51 | 2 | PS00798 | |
| Domain | Aldo/ket_reductase_CS | 3.24e-04 | 10 | 51 | 2 | IPR018170 | |
| Domain | Aldo/keto_reductase | 3.24e-04 | 10 | 51 | 2 | IPR020471 | |
| Domain | Phosphodiest | 3.24e-04 | 10 | 51 | 2 | PF01663 | |
| Domain | ALDOKETO_REDUCTASE_2 | 3.24e-04 | 10 | 51 | 2 | PS00062 | |
| Domain | ALDOKETO_REDUCTASE_3 | 3.24e-04 | 10 | 51 | 2 | PS00063 | |
| Domain | Phosphodiest/P_Trfase | 3.24e-04 | 10 | 51 | 2 | IPR002591 | |
| Domain | - | 8.56e-04 | 16 | 51 | 2 | 3.20.20.100 | |
| Domain | Gal_mutarotase_SF_dom | 9.68e-04 | 17 | 51 | 2 | IPR011013 | |
| Domain | NADP_OxRdtase_dom | 9.68e-04 | 17 | 51 | 2 | IPR023210 | |
| Domain | Aldo_ket_red | 9.68e-04 | 17 | 51 | 2 | PF00248 | |
| Domain | Aldo/ket_red/Kv-b | 9.68e-04 | 17 | 51 | 2 | IPR001395 | |
| Domain | - | 1.09e-03 | 18 | 51 | 2 | 3.30.470.20 | |
| Domain | ATP_grasp_subdomain_2 | 3.23e-03 | 31 | 51 | 2 | IPR013816 | |
| Domain | Alkaline_phosphatase_core | 3.23e-03 | 31 | 51 | 2 | IPR017850 | |
| Domain | Alkaline_Pase-like_a/b/a | 3.23e-03 | 31 | 51 | 2 | IPR017849 | |
| Domain | - | 3.23e-03 | 31 | 51 | 2 | 3.40.720.10 | |
| Domain | EGF_2 | 5.87e-03 | 265 | 51 | 4 | PS01186 | |
| Domain | Znf_FYVE_PHD | 7.55e-03 | 147 | 51 | 3 | IPR011011 | |
| Pubmed | 1.04e-07 | 7 | 51 | 3 | 8672144 | ||
| Pubmed | 3.95e-07 | 101 | 51 | 5 | 9872452 | ||
| Pubmed | ESCPE-1 mediates retrograde endosomal sorting of the SARS-CoV-2 host factor Neuropilin-1. | EPHB2 XYLT2 MAN2A1 ACLY ESYT1 HYAL3 LAMB1 PAM SMPD1 FGFR4 PIGO | 1.07e-06 | 1201 | 51 | 11 | 35696571 |
| Pubmed | Signal transduction by fibroblast growth factor receptor-4 (FGFR-4). Comparison with FGFR-1. | 2.11e-06 | 2 | 51 | 2 | 7518429 | |
| Pubmed | 2.11e-06 | 2 | 51 | 2 | 19179337 | ||
| Pubmed | 2.11e-06 | 2 | 51 | 2 | 23886516 | ||
| Pubmed | 6.32e-06 | 3 | 51 | 2 | 21281598 | ||
| Pubmed | 6.32e-06 | 3 | 51 | 2 | 21726077 | ||
| Pubmed | ACLY and ACC1 Regulate Hypoxia-Induced Apoptosis by Modulating ETV4 via α-ketoglutarate. | 6.32e-06 | 3 | 51 | 2 | 26452058 | |
| Pubmed | Acetyl-CoA carboxylase 1 is a suppressor of the adipocyte thermogenic program. | 2.10e-05 | 5 | 51 | 2 | 37163372 | |
| Pubmed | 2.10e-05 | 5 | 51 | 2 | 24612059 | ||
| Pubmed | In-depth proteomic analyses of exosomes isolated from expressed prostatic secretions in urine. | 2.27e-05 | 1070 | 51 | 9 | 23533145 | |
| Pubmed | 3.15e-05 | 6 | 51 | 2 | 9728334 | ||
| Pubmed | A novel transgenic mouse model of lysosomal storage disorder. | 3.15e-05 | 6 | 51 | 2 | 27659423 | |
| Pubmed | 4.41e-05 | 7 | 51 | 2 | 9632142 | ||
| Pubmed | EphB regulates L1 phosphorylation during retinocollicular mapping. | 4.41e-05 | 7 | 51 | 2 | 22579729 | |
| Pubmed | Genetic utility of broadly defined bipolar schizoaffective disorder as a diagnostic concept. | 5.87e-05 | 8 | 51 | 2 | 19567891 | |
| Pubmed | Chemerin, a novel adipokine in the regulation of angiogenesis. | 5.87e-05 | 8 | 51 | 2 | 20237162 | |
| Pubmed | Proteomic analysis of in vivo phosphorylated synaptic proteins. | 6.61e-05 | 53 | 51 | 3 | 15572359 | |
| Pubmed | Control of skeletal patterning by ephrinB1-EphB interactions. | 7.54e-05 | 9 | 51 | 2 | 12919674 | |
| Pubmed | Anuria, omphalocele, and perinatal lethality in mice lacking the CD34-related protein podocalyxin. | 1.15e-04 | 11 | 51 | 2 | 11435469 | |
| Pubmed | 1.21e-04 | 529 | 51 | 6 | 14621295 | ||
| Pubmed | FGF signaling is required for anterior but not posterior specification of the murine liver bud. | 1.38e-04 | 12 | 51 | 2 | 25302779 | |
| Pubmed | 1.63e-04 | 13 | 51 | 2 | 21406566 | ||
| Pubmed | A "double adaptor" method for improved shotgun library construction. | 1.89e-04 | 574 | 51 | 6 | 8619474 | |
| Pubmed | 2.19e-04 | 15 | 51 | 2 | 31417184 | ||
| Pubmed | 2.83e-04 | 17 | 51 | 2 | 19915572 | ||
| Pubmed | FGF8 Signaling Alters the Osteogenic Cell Fate in the Hard Palate. | 2.83e-04 | 17 | 51 | 2 | 29342370 | |
| Pubmed | 2.83e-04 | 17 | 51 | 2 | 18082680 | ||
| Pubmed | A cascading activity-based probe sequentially targets E1-E2-E3 ubiquitin enzymes. | 2.99e-04 | 88 | 51 | 3 | 27182664 | |
| Pubmed | Epithelial hedgehog signals pattern the intestinal crypt-villus axis. | 3.18e-04 | 18 | 51 | 2 | 15590741 | |
| Pubmed | 3.55e-04 | 19 | 51 | 2 | 26685326 | ||
| Pubmed | Tbx1 regulates oral epithelial adhesion and palatal development. | 3.94e-04 | 20 | 51 | 2 | 22371266 | |
| Pubmed | 4.10e-04 | 98 | 51 | 3 | 19554387 | ||
| Pubmed | A novel p53 regulator, C16ORF72/TAPR1, buffers against telomerase inhibition. | 4.20e-04 | 431 | 51 | 5 | 33660365 | |
| Pubmed | Control of TurboID-dependent biotinylation intensity in proximity ligation screens. | 4.35e-04 | 100 | 51 | 3 | 36966971 | |
| Pubmed | 4.35e-04 | 21 | 51 | 2 | 10579907 | ||
| Pubmed | 4.78e-04 | 22 | 51 | 2 | 15030763 | ||
| Pubmed | 4.78e-04 | 22 | 51 | 2 | 37532091 | ||
| Pubmed | 4.78e-04 | 22 | 51 | 2 | 28027321 | ||
| Pubmed | The nuclear interactome of DYRK1A reveals a functional role in DNA damage repair. | 5.15e-04 | 106 | 51 | 3 | 31024071 | |
| Pubmed | 5.23e-04 | 23 | 51 | 2 | 30814516 | ||
| Pubmed | 5.23e-04 | 23 | 51 | 2 | 26508642 | ||
| Pubmed | 5.23e-04 | 23 | 51 | 2 | 14662765 | ||
| Pubmed | 6.19e-04 | 25 | 51 | 2 | 24983448 | ||
| Pubmed | 6.70e-04 | 26 | 51 | 2 | 23435420 | ||
| Pubmed | Proteomic profiling of VCP substrates links VCP to K6-linked ubiquitylation and c-Myc function. | 7.38e-04 | 1353 | 51 | 8 | 29467282 | |
| Pubmed | 7.78e-04 | 28 | 51 | 2 | 8944226 | ||
| Pubmed | Extra-embryonic vasculature development is regulated by the transcription factor HAND1. | 7.78e-04 | 28 | 51 | 2 | 15073150 | |
| Pubmed | Primary cilia and Gli3 activity regulate cerebral cortical size. | 8.35e-04 | 29 | 51 | 2 | 21976438 | |
| Pubmed | 8.35e-04 | 29 | 51 | 2 | 16230531 | ||
| Pubmed | Integration of repulsive guidance cues generates avascular zones that shape mammalian blood vessels. | 9.54e-04 | 31 | 51 | 2 | 22076636 | |
| Pubmed | Crk proteins transduce FGF signaling to promote lens fiber cell elongation. | 9.54e-04 | 31 | 51 | 2 | 29360039 | |
| Pubmed | 9.54e-04 | 31 | 51 | 2 | 16123981 | ||
| Pubmed | 9.54e-04 | 31 | 51 | 2 | 22889265 | ||
| Pubmed | A dual-activity topoisomerase complex regulates mRNA translation and turnover. | 1.10e-03 | 1105 | 51 | 7 | 35748872 | |
| Pubmed | 1.15e-03 | 34 | 51 | 2 | 26220403 | ||
| Pubmed | Irisin Mediates Effects on Bone and Fat via αV Integrin Receptors. | 1.16e-03 | 1451 | 51 | 8 | 30550785 | |
| Pubmed | Multiple roles of epithelial heparan sulfate in stomach morphogenesis. | 1.22e-03 | 35 | 51 | 2 | 29700203 | |
| Pubmed | 1.36e-03 | 37 | 51 | 2 | 35863637 | ||
| Pubmed | 1.44e-03 | 568 | 51 | 5 | 9110174 | ||
| Cytoband | Ensembl 112 genes in cytogenetic band chr5q21 | 2.71e-03 | 69 | 51 | 2 | chr5q21 | |
| GeneFamily | Aldo-keto reductases | 2.57e-04 | 15 | 29 | 2 | 399 | |
| GeneFamily | Fibronectin type III domain containing | 2.10e-03 | 160 | 29 | 3 | 555 | |
| GeneFamily | Sterile alpha motif domain containing | 8.73e-03 | 88 | 29 | 2 | 760 | |
| Coexpression | KIM_ALL_DISORDERS_DURATION_CORR_DN | 9.25e-06 | 145 | 51 | 5 | M2113 | |
| Coexpression | PRC2_EZH2_UP.V1_UP | 3.58e-05 | 192 | 51 | 5 | M2739 | |
| Coexpression | GSE22025_UNTREATED_VS_PROGESTERONE_TREATED_CD4_TCELL_UP | 4.14e-05 | 198 | 51 | 5 | M8377 | |
| Coexpression | GSE20151_CTRL_VS_FUSOBACT_NUCLEATUM_NEUTROPHIL_UP | 4.14e-05 | 198 | 51 | 5 | M4309 | |
| Coexpression | GSE37532_WT_VS_PPARG_KO_VISCERAL_ADIPOSE_TISSUE_TREG_DN | 4.35e-05 | 200 | 51 | 5 | M8962 | |
| Coexpression | HALLMARK_GLYCOLYSIS | 4.35e-05 | 200 | 51 | 5 | M5937 | |
| Coexpression | GSE360_L_DONOVANI_VS_L_MAJOR_DC_UP | 4.35e-05 | 200 | 51 | 5 | M5192 | |
| Coexpression | KIM_ALL_DISORDERS_OLIGODENDROCYTE_NUMBER_CORR_UP | 9.72e-05 | 755 | 51 | 8 | M2105 | |
| ToppCell | Children_(3_yrs)-Mesenchymal-matrix_fibroblast_1_cell-D032|Children_(3_yrs) / Lineage, Cell type, age group and donor | 2.76e-06 | 193 | 51 | 5 | b3ad5ff480d99217f36cc7471e5a96a519ddb409 | |
| ToppCell | Bronchial-NucSeq-Stromal-Fibroblastic-Fibro_alveolar|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations | 3.28e-06 | 200 | 51 | 5 | e8462395fee0a532d1e7ec7f1795f28c42af6541 | |
| ToppCell | Parenchymal-NucSeq-Stromal-Fibroblastic|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations | 3.28e-06 | 200 | 51 | 5 | 311fab076f2ceb258e3970eb21e39344b894042a | |
| ToppCell | Parenchymal-NucSeq-Stromal-Fibroblastic-Fibro_alveolar|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations | 3.28e-06 | 200 | 51 | 5 | 34f52003988ce6329d8deeee1ab875fa77e01e9d | |
| ToppCell | PBMC_fresh-frozen-Mild-Moderate_progression_d12-25-Lymphocytic-Lymphocytic_T-mature_alpha-beta_T_cell-T_CD8_c01-LEF1|Mild-Moderate_progression_d12-25 / Compartment, severity and other cell annotations on 10x 3' data (130k) | 3.46e-05 | 161 | 51 | 4 | 5fba13f0aa5002f7eefe219e2c6a07e163f1a50d | |
| ToppCell | 367C-Fibroblasts-Fibroblast-G-|367C / Donor, Lineage, Cell class and subclass (all cells) | 4.09e-05 | 168 | 51 | 4 | b8c65542a0701ae31f49d332d87a64578e24b4e3 | |
| ToppCell | 367C-Fibroblasts-Fibroblast-G|367C / Donor, Lineage, Cell class and subclass (all cells) | 4.09e-05 | 168 | 51 | 4 | 8c95093b1ea45826f62893edd3c410fe53b563a4 | |
| ToppCell | E16.5-Endothelial-Endothelial_blood-vessel-Macrovascular_EC-AEC-AEC_prolif|E16.5 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif | 4.28e-05 | 170 | 51 | 4 | 55fe16d98ea284d05fb899888e4569c685644c7b | |
| ToppCell | Thalamus-Neuronal-Excitatory|Thalamus / BrainAtlas - Mouse McCarroll V32 | 4.90e-05 | 176 | 51 | 4 | d2bbf13d21fb7582d7e5f90cd61a4ebe1cfccd66 | |
| ToppCell | 10x3'2.3-week_17-19-Lymphocytic_T-T_NK-NK_T_cell|week_17-19 / cell types per 3 fetal stages;per 3',per 5' | 5.12e-05 | 178 | 51 | 4 | a34bb693b72684cbd97ac9efff77d2d14e41be75 | |
| ToppCell | wk_15-18-Epithelial-PNS-KCNIP4+_neuron|wk_15-18 / Celltypes from embryonic and fetal-stage human lung | 5.23e-05 | 179 | 51 | 4 | e20bfdfb6d5af8556eb66b81a19fbe4e3e28334a | |
| ToppCell | 5'-Parenchyma_lung-Mesenchymal-Mesenchymal_Myocytic-pericyte_cell-Pericytes-Pericytes_L.2.3.3.0|5' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5 | 5.23e-05 | 179 | 51 | 4 | dc6cd46fa652b296ddbc41855f6377946d0a4cdc | |
| ToppCell | droplet-Liver-LIVER_HEP-30m-Mesenchymal-hepatic_stellate_cell|Liver / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 5.95e-05 | 185 | 51 | 4 | 40e958511790e84321da5ccf735f9974c06a0263 | |
| ToppCell | droplet-Liver-LIVER_HEP-30m-Mesenchymal-hepatic_stellate_cell|Liver / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 5.95e-05 | 185 | 51 | 4 | 5f2eeba80aff145e85cfd81e2890a155406badb9 | |
| ToppCell | droplet-Liver-LIVER_HEP-30m-Mesenchymal|Liver / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 5.95e-05 | 185 | 51 | 4 | f814ec9d4ade717a0109398e9768d0d66f09317b | |
| ToppCell | Fetal_29-31_weeks-Mesenchymal-pericyte_cell-D088|Fetal_29-31_weeks / Lineage, Cell type, age group and donor | 5.95e-05 | 185 | 51 | 4 | a7dba7db79275884b2a93d8a16f2e0c739e71370 | |
| ToppCell | Control-Fibroblasts-Alveolar_FB|Control / group, cell type (main and fine annotations) | 6.20e-05 | 187 | 51 | 4 | 92d468dde81125d51daf7abd4703741abe1ab91c | |
| ToppCell | LPS_only-Stromal_mesenchymal-Matrix_Fibroblast-MatrixFB|LPS_only / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 6.46e-05 | 189 | 51 | 4 | 2a22b9fae70afb3dab8476f9c00e48a4df756410 | |
| ToppCell | wk_20-22-Hematologic-Myeloid-APOE+_Mac1|wk_20-22 / Celltypes from embryonic and fetal-stage human lung | 6.73e-05 | 191 | 51 | 4 | c204ec71b7755b46a18d3a6aa84d0f407145ce9d | |
| ToppCell | renal_medulla_nuclei-Renal_AKI_(acute_kidney_injury)-Epithelial-Intermediate_tubule_epithelial_cell|Renal_AKI_(acute_kidney_injury) / Celltypes from Cells and Nuclei per compartment and clinical group | 6.73e-05 | 191 | 51 | 4 | d0e9afe7b6334dd515d3e68892efdc76347a55e5 | |
| ToppCell | nucseq-Mesenchymal-Fibroblastic-Fibroblastic_2-AF1|nucseq / Celltype signatures by Technology, Lineage, Lineage_subclass, Celltype_group, Cell_type2 | 6.73e-05 | 191 | 51 | 4 | 6688cee34beee4f151ac17fccbc9c26a9aad72e1 | |
| ToppCell | nucseq-Mesenchymal-Fibroblastic-Fibroblastic_2|nucseq / Celltype signatures by Technology, Lineage, Lineage_subclass, Celltype_group, Cell_type2 | 6.87e-05 | 192 | 51 | 4 | 99ce9e3c4c50cf64ebb62145f2b5420efa0db309 | |
| ToppCell | Posterior_cortex-Neuronal|Posterior_cortex / BrainAtlas - Mouse McCarroll V32 | 7.01e-05 | 193 | 51 | 4 | b4989e3436e84dbec3789b46057e0f7a0ebf09d4 | |
| ToppCell | renal_papilla_nuclei-Hypertensive_with+without-CKD|renal_papilla_nuclei / Celltypes from Cells and Nuclei per compartment and clinical group | 7.01e-05 | 193 | 51 | 4 | ca7c0a4ceb05bced90f6cdc53d278e547fb241e9 | |
| ToppCell | Mesenchymal-matrix_fibroblast_1_cell|World / Lineage, Cell type, age group and donor | 7.01e-05 | 193 | 51 | 4 | acad568621ed677031797b8c2e34dafea798d681 | |
| ToppCell | Children_(3_yrs)-Mesenchymal-matrix_fibroblast_1_cell|Children_(3_yrs) / Lineage, Cell type, age group and donor | 7.01e-05 | 193 | 51 | 4 | 99525545552b371c86b18b6ea6f4897dc6e9a9ec | |
| ToppCell | Adult-Mesenchymal-matrix_fibroblast_1_cell-D231|Adult / Lineage, Cell type, age group and donor | 7.01e-05 | 193 | 51 | 4 | ef2f456c094e6e3c6ee81e0668c953cb8d0e1c0a | |
| ToppCell | Fetal_29-31_weeks-Mesenchymal-matrix_fibroblast_1_cell-D062|Fetal_29-31_weeks / Lineage, Cell type, age group and donor | 7.15e-05 | 194 | 51 | 4 | 35f132cc38ac133be01834ed0946188aa0757eb4 | |
| ToppCell | Children_(3_yrs)-Mesenchymal-matrix_fibroblast_1_cell-D139|Children_(3_yrs) / Lineage, Cell type, age group and donor | 7.15e-05 | 194 | 51 | 4 | e93de9428c986b8943fc169258847c650cfab0e5 | |
| ToppCell | Fetal_29-31_weeks-Mesenchymal-matrix_fibroblast_1_cell|Fetal_29-31_weeks / Lineage, Cell type, age group and donor | 7.15e-05 | 194 | 51 | 4 | 011e14d9ed1393275f892060e7708ffadcd0767f | |
| ToppCell | 5'-Parenchyma_lung-Mesenchymal-Mesenchymal_Myocytic-pericyte_cell-Pericytes|5' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5 | 7.15e-05 | 194 | 51 | 4 | 8f19e553f18c313c2a2ff9453884b9484b255d71 | |
| ToppCell | 5'-Parenchyma_lung-Mesenchymal-Mesenchymal_Myocytic-pericyte_cell|5' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5 | 7.15e-05 | 194 | 51 | 4 | 67fbb81b7d20cb63be27b2a2beea5b5689f8e08c | |
| ToppCell | Adult-Mesenchymal-matrix_fibroblast_1_cell|Adult / Lineage, Cell type, age group and donor | 7.29e-05 | 195 | 51 | 4 | 61c9e09fc84d1012e472185d70ad0a06cee30d6e | |
| ToppCell | COVID-19-Fibroblasts-Alveolar_FB|COVID-19 / group, cell type (main and fine annotations) | 7.29e-05 | 195 | 51 | 4 | 603050beeb33c331d4b2e3fa46cae3f3e0e4bdc7 | |
| ToppCell | Adult-Mesenchymal-matrix_fibroblast_1_cell-D122|Adult / Lineage, Cell type, age group and donor | 7.29e-05 | 195 | 51 | 4 | aa0add081881d349099d12efca5cdee098038d4e | |
| ToppCell | Bronchial-NucSeq-Stromal-Peri/Epineurial_-NAF_endoneurial|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations | 7.58e-05 | 197 | 51 | 4 | 6806ec223e542f0475303698eb78c1cc527f5c6b | |
| ToppCell | 3'-GW_trimst-1-SmallIntestine-Neuronal-neurons_B-Branch_B2_(eMN)|GW_trimst-1 / Celltypes from developing, pediatric, Crohn's, & adult GI tract | 7.73e-05 | 198 | 51 | 4 | 85881637641d8996be2edc65c4bceff0433135e7 | |
| ToppCell | Adult-Mesenchymal|Adult / Lineage, Cell type, age group and donor | 7.73e-05 | 198 | 51 | 4 | 26e55b409db2a1637c95fae7c54b0abea1ef550c | |
| ToppCell | Control_saline-Mesenchymal_fibroblastic-Fibroblasts-Activated_MatrixFB|Control_saline / Treatment groups by lineage, cell group, cell type | 7.73e-05 | 198 | 51 | 4 | 0c4d2c68a42f8a9e964e2dd28092fe75f5216834 | |
| ToppCell | Parenchymal-NucSeq-Stromal|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations | 8.04e-05 | 200 | 51 | 4 | cf433f9b43d7db07acaf70e060f8f77c974e72f3 | |
| ToppCell | Control_saline-Mesenchymal_fibroblastic|Control_saline / Treatment groups by lineage, cell group, cell type | 8.04e-05 | 200 | 51 | 4 | 64ae5cf6cb4fc94cf1052abd82648f6b8e6445fe | |
| ToppCell | Bronchial-NucSeq-Stromal|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations | 8.04e-05 | 200 | 51 | 4 | 389cc775c8419d90fb77cd794376d2160a7bf44e | |
| ToppCell | Control_saline-Mesenchymal_fibroblastic-Fibroblasts|Control_saline / Treatment groups by lineage, cell group, cell type | 8.04e-05 | 200 | 51 | 4 | a1fc74c1b27e104895910bc7cdce7ba33d30df7e | |
| ToppCell | Control_saline-Mesenchymal_fibroblastic-Fibroblasts-MatrixFB|Control_saline / Treatment groups by lineage, cell group, cell type | 8.04e-05 | 200 | 51 | 4 | bd8cf33502adea320e91ca2af14e1911d88ad374 | |
| Drug | Diphenylpyraline hydrochloride [132-18-3]; Down 200; 12.6uM; PC3; HT_HG-U133A | 2.64e-07 | 196 | 51 | 7 | 3743_DN | |
| Drug | Betaine | 1.36e-06 | 157 | 51 | 6 | ctd:D001622 | |
| Drug | Bumetanide [28395-03-1]; Down 200; 11uM; PC3; HT_HG-U133A | 4.78e-06 | 195 | 51 | 6 | 5117_DN | |
| Drug | Isosorbide dinitrate [87-33-2]; Down 200; 17uM; MCF7; HT_HG-U133A | 4.78e-06 | 195 | 51 | 6 | 4742_DN | |
| Drug | Betazole hydrochloride; Down 200; 27uM; PC3; HT_HG-U133A | 4.92e-06 | 196 | 51 | 6 | 6344_DN | |
| Drug | spiromesifen | 4.92e-06 | 2 | 51 | 2 | CID009907412 | |
| Drug | Reserpinic acid hydrochloride; Down 200; 9.2uM; PC3; HT_HG-U133A | 5.21e-06 | 198 | 51 | 6 | 6603_DN | |
| Drug | Thalidomide [50-35-1]; Up 200; 15.4uM; HL60; HG-U133A | 5.21e-06 | 198 | 51 | 6 | 1411_UP | |
| Drug | AC1L18AJ | 4.90e-05 | 5 | 51 | 2 | CID000000018 | |
| Drug | Fenbufen [36330-85-5]; Down 200; 15.8uM; MCF7; HT_HG-U133A | 6.94e-05 | 192 | 51 | 5 | 4743_DN | |
| Drug | Chlorpromazine hydrochloride [69-09-0]; Up 200; 11.2uM; HL60; HT_HG-U133A | 7.11e-05 | 193 | 51 | 5 | 1864_UP | |
| Drug | CP-690334-01 [459212-38-5]; Down 200; 10uM; PC3; HT_HG-U133A | 7.11e-05 | 193 | 51 | 5 | 4558_DN | |
| Drug | Clotrimazole [23593-75-1]; Down 200; 11.6uM; PC3; HT_HG-U133A | 7.11e-05 | 193 | 51 | 5 | 5726_DN | |
| Drug | paclitaxel; Down 200; 0.1uM; MCF7; HG-U133A | 7.29e-05 | 194 | 51 | 5 | 640_DN | |
| Drug | Ethisterone [434-03-7]; Up 200; 12.8uM; PC3; HT_HG-U133A | 7.29e-05 | 194 | 51 | 5 | 3783_UP | |
| Drug | (S)-(-)-Cycloserine [339-72-0]; Down 200; 39.2uM; PC3; HT_HG-U133A | 7.29e-05 | 194 | 51 | 5 | 4524_DN | |
| Drug | Clindamycin hydrochloride [21462-39-5]; Down 200; 8.6uM; MCF7; HT_HG-U133A | 7.47e-05 | 195 | 51 | 5 | 7172_DN | |
| Drug | Procyclidine hydrochloride [1508-76-5]; Up 200; 12.4uM; MCF7; HT_HG-U133A | 7.47e-05 | 195 | 51 | 5 | 4817_UP | |
| Drug | Piretanide [55837-27-9]; Down 200; 11uM; MCF7; HT_HG-U133A | 7.65e-05 | 196 | 51 | 5 | 3567_DN | |
| Drug | Methotrexate [59-05-2]; Up 200; 8.8uM; PC3; HT_HG-U133A | 7.65e-05 | 196 | 51 | 5 | 6318_UP | |
| Drug | 3-Acetamidocoumarin [779-30-6]; Down 200; 19.6uM; HL60; HT_HG-U133A | 7.65e-05 | 196 | 51 | 5 | 2941_DN | |
| Drug | PF-00539745-00 [351321-33-0]; Down 200; 10uM; MCF7; HT_HG-U133A | 7.65e-05 | 196 | 51 | 5 | 5974_DN | |
| Drug | Liothyronine [6893-02-3]; Down 200; 6.2uM; PC3; HT_HG-U133A | 7.65e-05 | 196 | 51 | 5 | 6602_DN | |
| Drug | Naloxone hydrochloride [357-08-4]; Down 200; 11uM; PC3; HT_HG-U133A | 7.65e-05 | 196 | 51 | 5 | 4645_DN | |
| Drug | 1-phenylbiguanide hydrochloride; Up 200; 10uM; MCF7; HG-U133A | 7.84e-05 | 197 | 51 | 5 | 22_UP | |
| Drug | Sulfanilamide [63-74-1]; Down 200; 23.2uM; PC3; HT_HG-U133A | 7.84e-05 | 197 | 51 | 5 | 4474_DN | |
| Drug | Raloxifene hydrochloride [82640-04-8]; Down 200; 7.8uM; HL60; HT_HG-U133A | 7.84e-05 | 197 | 51 | 5 | 2738_DN | |
| Drug | Succinylsulfathiazole [116-43-8]; Up 200; 11.2uM; MCF7; HT_HG-U133A | 7.84e-05 | 197 | 51 | 5 | 2821_UP | |
| Drug | STOCK1N-35874; Down 200; 14uM; PC3; HT_HG-U133A | 7.84e-05 | 197 | 51 | 5 | 6583_DN | |
| Drug | GSK-3 Inhibitor IX; Down 200; 0.5uM; PC3; HT_HG-U133A | 8.03e-05 | 198 | 51 | 5 | 7048_DN | |
| Drug | Dipyridamole [58-32-2]; Up 200; 8uM; MCF7; HT_HG-U133A | 8.03e-05 | 198 | 51 | 5 | 5617_UP | |
| Drug | Adamantamine fumarate [80789-67-9]; Down 200; 9.6uM; MCF7; HT_HG-U133A | 8.22e-05 | 199 | 51 | 5 | 4806_DN | |
| Drug | Oleandomycin phosphate [7060-74-4]; Down 200; 5uM; PC3; HT_HG-U133A | 8.22e-05 | 199 | 51 | 5 | 4615_DN | |
| Drug | Diclofenac sodium [15307-79-6]; Down 200; 12.6uM; MCF7; HT_HG-U133A | 8.22e-05 | 199 | 51 | 5 | 7215_DN | |
| Drug | 1,1-dimethylbiguanide hydrochloride; Up 200; 10uM; MCF7; HG-U133A | 8.22e-05 | 199 | 51 | 5 | 61_UP | |
| Drug | 1,2-dithiol-3-thione | 8.29e-05 | 829 | 51 | 9 | ctd:C049325 | |
| Drug | 2-phenylbenzothiazole | 1.03e-04 | 7 | 51 | 2 | CID000013439 | |
| Drug | trimethylamine-cyanoborane | 1.37e-04 | 8 | 51 | 2 | CID006328234 | |
| Disease | Rhabdomyosarcoma | 2.80e-04 | 15 | 49 | 2 | C0035412 | |
| Disease | lung squamous cell carcinoma (is_implicated_in) | 7.28e-04 | 24 | 49 | 2 | DOID:3907 (is_implicated_in) | |
| Disease | Drugs used in diabetes use measurement | 8.51e-04 | 255 | 49 | 4 | EFO_0009924 | |
| Disease | intestinal permeability measurement | 8.56e-04 | 26 | 49 | 2 | EFO_0011031 | |
| Disease | Carcinoma, Basal Cell | 1.07e-03 | 29 | 49 | 2 | C4721806 | |
| Disease | drug dependence | 1.55e-03 | 35 | 49 | 2 | EFO_0003890 |
| Peptide | Gene | Start | Entry |
|---|---|---|---|
| LAVPKHPYAAMENWG | 396 | Q9UKU6 | |
| WPEEHYAMVALNFVP | 241 | Q719I0 | |
| YMSHRELPAWVSFPD | 121 | Q9BSJ8 | |
| HYWVGLDISPAMLDE | 76 | O43709 | |
| GWLPEVISLHPGYMD | 271 | Q8N7X0 | |
| LLMWRDHPEYPFHDE | 311 | P51857 | |
| CWGTDYHLGMAIPDI | 591 | O43506 | |
| PFDMVYWTGDIPAHD | 271 | P17405 | |
| PELYGLMRECWHAAP | 716 | P22455 | |
| RHMFHVAWVDPEDPY | 1731 | Q13085 | |
| FHMEEALDWPGVYLL | 496 | P19021 | |
| CPEPGHKGMDYRDWV | 16 | Q96SN7 | |
| ESPHERMHPYIELAW | 136 | Q96SN7 | |
| PLYDEVQMGPWDLHW | 1191 | O60500 | |
| VQMGPWDLHWPEDTY | 1196 | O60500 | |
| LLGDEHWATDPDMYL | 116 | Q9NQU5 | |
| WAIDPFGHSPTMAYL | 286 | Q16706 | |
| GLPRDHPESYHSFMW | 76 | P46926 | |
| YIRGDMDHIEDPSWT | 116 | P48051 | |
| YWPPLTHAAFIAMAG | 2501 | Q9UPA5 | |
| PHEPDGVALVWNMKY | 306 | Q13409 | |
| MVHPPSGWEEVSGYD | 36 | P29323 | |
| YWEDPDDMGHHLGPD | 186 | Q9UJA9 | |
| MDAGSLYEPVSPHWF | 31 | O94830 | |
| AHAAGVLMEPDDWPY | 841 | Q9H3R0 | |
| LCMDFYHDLPWRPAE | 311 | P07942 | |
| AEDKPYAELWMGTHP | 41 | P34949 | |
| DALAQAPMDGWPHSY | 176 | Q86XD5 | |
| MGEGDAFWAPSVLPH | 1 | P57721 | |
| APWHLRYLGQPEMGD | 81 | Q9BUE0 | |
| EWDHPEHPNGIMIGY | 951 | O94856 | |
| YMWDEEGLEPIGNVH | 511 | Q9H7U1 | |
| PRHWEAMSAIVGYPL | 851 | Q8WXX0 | |
| DPGQMEAFLHLWPDG | 371 | O43820 | |
| WLFQHLMHPYPTEDE | 306 | Q96KN3 | |
| ATAMLFDPAAWLHGP | 2851 | Q5T011 | |
| LWEPMEHHGDPNIFY | 1341 | Q5QGS0 | |
| PEWVHDKADYMPETR | 946 | Q13635 | |
| IHDWGLFAMEPIAAD | 1836 | Q9UPS6 | |
| MPECWDGEHDIETPY | 1 | Q9ULP0 | |
| EVIGHPVMPAYWALG | 1211 | P14410 | |
| HPWDDISYVLPEHMS | 1086 | P53396 | |
| WALHFLMDAQPGSEP | 441 | Q96AP0 | |
| HYPIERGLVTGWDDM | 71 | Q8TDG2 | |
| LMHWPYAFERGDNPF | 111 | P14550 | |
| LWHGAPPMAAVSLAY | 881 | Q8TCY9 | |
| HPNWQFVDVYGMDPE | 26 | P15374 | |
| WHIMIPSDIEPDGSY | 2171 | Q8IZQ1 | |
| LDCWDGPDGMPVIYH | 366 | P19174 | |
| YPTMDSGEWDVLIAH | 216 | Q8TEQ8 | |
| WAHNMGSEDYDCIPP | 126 | Q9BXT5 | |
| ARGWAHIEPMYLPPD | 216 | Q9BQ50 | |
| ASWLHAGPPHNEYME | 761 | Q9H1B5 |